28190742|t|PCV13 serotype decrease in Italian adolescents and adults in the post- PCV13 era: Herd protection from children or secular trend?
28190742|a|In 2010 PCV13 replaced PCV7 in the pediatric vaccination schedule for Italian children. While a strong herd effect was demonstrated for PCV7, a possible herd effect due to PCV13 is still under debate. Our aim was to evaluate differences in the distribution of pneumococcal serotypes between the pre and post- PCV13 eras in unvaccinated Italian adolescents and adults with laboratory-confirmed pneumococcal infection from 3 Italian Regions with a high rate of PCV13 vaccination of children. Adolescents and adults admitted with laboratory-confirmed pneumococcal infection in the hospitals of 3 Italian Regions (Friuli-Venezia Giulia, Emilia Romagna, and Tuscany) between April 2006 and June 2016 were included in the study. Diagnosis of pneumococcal infection and serotyping were performed with Real Time PCR directly on normally sterile fluids or on culture isolates. 523 patients with laboratory-confirmed pneumococcal infection were enrolled (Male / Female ratio was 300/223, 1.3; median age 67.1, IQR 53.4-74.9). None of the patients had been vaccinated with any pneumococcal vaccine; 96.4% were serotyped. Overall, the most frequent serotypes were 3 (67/504, 13.3%), 8 (43/504, 8.5%), and 19A (38/504, 7.5%). Serotype distribution differed among age classes and clinical presentations. Overall, PCV13 serotypes accounted for 47.6% of cases: 62.3% in the pre- PCV13 era and 45.0% in the post- PCV13 era; (p=0.005 OR=2.03; CL 95%: 1.2-3.3). Serotype 7F accounted for 12/77 (15.6%) of all serotypes in the pre- PCV13 period and for 12/427 (2.8%) in the post- PCV13 period and was the only serotype significantly contributing to the difference in percentage between pre and post- PCV13 eras. Our study demonstrated a difference in percentage in serotype distribution in adolescents and adults laboratory-confirmed pneumococcal infection between the pre and post- PCV13 eras. This difference is mainly due to the decrease of serotype 7F. Thus, in order to decrease disease burden, adults and in particular the elderly should be offered a specific vaccination program.
28190742	0	5	PCV13	T121,T129	C3152625
28190742	6	14	serotype	T170	C0449943
28190742	27	34	Italian	T098	C0337810
28190742	35	46	adolescents	T100	C0205653
28190742	51	57	adults	T100	C0001675
28190742	71	76	PCV13	T121,T129	C3152625
28190742	77	80	era	T079	C0681698
28190742	82	97	Herd protection	T039	C1135927
28190742	103	111	children	T100	C0008059
28190742	115	128	secular trend	T079	C0681685
28190742	138	143	PCV13	T121,T129	C3152625
28190742	153	157	PCV7	T116,T129	C3852780
28190742	165	174	pediatric	T080	C1521725
28190742	175	186	vaccination	T061	C0042196
28190742	200	207	Italian	T098	C0337810
28190742	208	216	children	T100	C0008059
28190742	233	244	herd effect	T039	C1135927
28190742	266	270	PCV7	T116,T129	C3852780
28190742	283	294	herd effect	T039	C1135927
28190742	302	307	PCV13	T121,T129	C3152625
28190742	390	402	pneumococcal	T007	C0038410
28190742	403	412	serotypes	T170	C0449943
28190742	439	444	PCV13	T121,T129	C3152625
28190742	445	449	eras	T079	C0681698
28190742	453	465	unvaccinated	T033	C0243095
28190742	466	473	Italian	T098	C0337810
28190742	474	485	adolescents	T100	C0205653
28190742	490	496	adults	T100	C0001675
28190742	502	522	laboratory-confirmed	T059	C0022885
28190742	523	545	pneumococcal infection	T047	C0032269
28190742	553	568	Italian Regions	T083	C0022277
28190742	589	594	PCV13	T121,T129	C3152625
28190742	595	606	vaccination	T061	C0042196
28190742	610	618	children	T100	C0008059
28190742	620	631	Adolescents	T100	C0205653
28190742	636	642	adults	T100	C0001675
28190742	657	677	laboratory-confirmed	T059	C0022885
28190742	678	700	pneumococcal infection	T047	C0032269
28190742	708	717	hospitals	T073,T093	C0019994
28190742	723	738	Italian Regions	T083	C0022277
28190742	740	761	Friuli-Venezia Giulia	T083	C0017446
28190742	763	777	Emilia Romagna	T083	C0017446
28190742	783	790	Tuscany	T083	C0017446
28190742	853	862	Diagnosis	T033	C0011900
28190742	866	888	pneumococcal infection	T047	C0032269
28190742	893	903	serotyping	T170	C0449943
28190742	924	937	Real Time PCR	T063	C1709846
28190742	959	996	sterile fluids or on culture isolates	T059	C1272855
28190742	1002	1010	patients	T101	C0030705
28190742	1016	1036	laboratory-confirmed	T059	C0022885
28190742	1037	1059	pneumococcal infection	T047	C0032269
28190742	1075	1079	Male	T032	C0086582
28190742	1082	1088	Female	T032	C0086287
28190742	1158	1166	patients	T101	C0030705
28190742	1176	1186	vaccinated	T033	C1519885
28190742	1196	1216	pneumococcal vaccine	T121,T129	C0358314
28190742	1229	1238	serotyped	T170	C0449943
28190742	1267	1276	serotypes	T170	C0449943
28190742	1282	1283	3	T007	C0522401
28190742	1301	1302	8	T007	C1628956
28190742	1323	1326	19A	T007	C1532745
28190742	1343	1351	Serotype	T170	C0449943
28190742	1396	1418	clinical presentations	T170	C2708283
28190742	1429	1434	PCV13	T121,T129	C3152625
28190742	1435	1444	serotypes	T170	C0449943
28190742	1493	1498	PCV13	T121,T129	C3152625
28190742	1499	1502	era	T079	C0681698
28190742	1526	1531	PCV13	T121,T129	C3152625
28190742	1532	1535	era	T079	C0681698
28190742	1573	1584	Serotype 7F	T007	C0522403
28190742	1620	1629	serotypes	T170	C0449943
28190742	1642	1647	PCV13	T121,T129	C3152625
28190742	1648	1654	period	T079	C0681698
28190742	1690	1695	PCV13	T121,T129	C3152625
28190742	1696	1702	period	T079	C0681698
28190742	1720	1728	serotype	T170	C0449943
28190742	1810	1815	PCV13	T121,T129	C3152625
28190742	1816	1820	eras	T079	C0681698
28190742	1875	1883	serotype	T170	C0449943
28190742	1900	1911	adolescents	T100	C0205653
28190742	1916	1922	adults	T100	C0001675
28190742	1923	1943	laboratory-confirmed	T059	C0022885
28190742	1944	1966	pneumococcal infection	T047	C0032269
28190742	1993	1998	PCV13	T121,T129	C3152625
28190742	1999	2003	eras	T079	C0681698
28190742	2054	2065	serotype 7F	T007	C0522403
28190742	2094	2108	disease burden	T081	C0162698
28190742	2110	2116	adults	T100	C0001675
28190742	2176	2187	vaccination	T061	C0042196